Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy
- PMID: 10504505
- DOI: 10.1046/j.1523-1755.1999.00675.x
Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy
Abstract
Background: Previous studies have shown that short-term treatment with adrenocorticotrophic hormone (ACTH) has a strong and rapid lipid-lowering effect. In this long-term study of nephrotic patients with idiopathic membranous nephropathy, the influence of ACTH on the serum lipoprotein profile and glomerular function as well as the dose-effect relationship was investigated.
Methods: Fourteen patients received ACTH intramuscularly at increasing doses during 56 days. Serum concentrations of lipids, lipoproteins, and apolipoproteins as well as variables of glomerular function were analyzed, and the side-effects were recorded. ACTH treatment, in the estimated optimal dosage, was then continued in five patients with severe steroid-resistant nephrotic syndrome. In these five patients, the total treatment period was 12 months, and the follow-up time after discontinuing treatment was 18 months.
Results: Taking both the statistically significant therapeutic effects and the modest side-effects into consideration, the optimal dosage of ACTH was estimated to be 1 mg twice per week. At that dose, reductions by 30 to 60% in the serum concentrations of cholesterol, triglycerides, apolipoprotein B, and lipoprotein(a) were observed, whereas the serum concentrations of high-density lipoprotein cholesterol and apolipoprotein AI rose by 30 to 40%. In addition, the urinary albumin excretion decreased by 90%, and the glomerular filtration rate increased by 25%. Deterioration was observed in all cases when ACTH was discontinued after a treatment duration of 56 days. However, the five patients in whom ACTH therapy was resumed were still in remission 18 months after discontinuance of treatment.
Conclusions: In nephrotic patients with idiopathic membranous nephropathy, treatment with ACTH 1 mg twice per week was associated with significant long-term improvements in serum lipoprotein pattern and glomerular function.
Similar articles
-
Leveraging melanocortin pathways to treat glomerular diseases.Adv Chronic Kidney Dis. 2014 Mar;21(2):134-51. doi: 10.1053/j.ackd.2013.09.004. Adv Chronic Kidney Dis. 2014. PMID: 24602463 Free PMC article. Review.
-
Effects of different doses of adrenocorticotrophic hormone on the serum lipoprotein profile in healthy subjects.Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):86-90. doi: 10.1111/j.1742-7843.2005.pto_108.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15998354 Clinical Trial.
-
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8. Nephrol Dial Transplant. 2014. PMID: 24714414 Free PMC article. Clinical Trial.
-
The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins.Metabolism. 2006 Aug;55(8):1083-7. doi: 10.1016/j.metabol.2006.04.001. Metabolism. 2006. PMID: 16839845 Clinical Trial.
-
Pitavastatin: novel effects on lipid parameters.Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
Cited by
-
A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.Med Sci Monit. 2021 Feb 7;27:e930097. doi: 10.12659/MSM.930097. Med Sci Monit. 2021. PMID: 33550324 Free PMC article. Review.
-
Leveraging melanocortin pathways to treat glomerular diseases.Adv Chronic Kidney Dis. 2014 Mar;21(2):134-51. doi: 10.1053/j.ackd.2013.09.004. Adv Chronic Kidney Dis. 2014. PMID: 24602463 Free PMC article. Review.
-
Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases.Kidney Med. 2019 Jan 14;1(1):31-35. doi: 10.1016/j.xkme.2018.12.003. eCollection 2019 Jan-Feb. Kidney Med. 2019. PMID: 32734181 Free PMC article.
-
Apolipoprotein M.Lipids Health Dis. 2004 Oct 4;3:21. doi: 10.1186/1476-511X-3-21. Lipids Health Dis. 2004. PMID: 15461812 Free PMC article.
-
Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness.BMC Nephrol. 2014 May 8;15:74. doi: 10.1186/1471-2369-15-74. BMC Nephrol. 2014. PMID: 24886340 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical